Author:
Kohan Donald E.,Cleland John G.,Rubin Lewis J.,Theodorescu Dan,Barton Matthias
Funder
National Institutes of Health
FP7 — The European Union Seventh Framework Programme 2007–2011
Swiss National Science Foundation
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference198 articles.
1. Bosentan, a selective and more potent antagonist for Atractaspis envenomation than the specific antivenom;Abd-Elsalam;Toxicon,2011
2. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention;Ahn;J Clin Invest,2004
3. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial;Anand;Lancet,2004
4. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD);Andress;Life Sci,2012
5. Cloning and expression of a cDNA encoding an endothelin receptor;Arai;Nature,1990
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献